A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder c...
Age: 18 years - 66+
Gender: All
Transcranial Magnetic Stimulation in Misophonia
The purpose of the project is to assess the efficacy of parietal transcranial magnetic
stimulation in misophonia. N=60 participants will undergo two transcranial magnetic
stimulation sessions: one inhibitory and another excitatory. During both sessions, the
parietal ...
Age: 18 - 55 years
Gender: All
MAGIC Ruxolitinib for aGVHD
This clinical trial will study ruxolitinib-based treatment of acute
graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell
transplant. Acute GVHD occurs when donor cells attack the healthy tissue of the body. The
most common symptoms ...
Age: 18 years - 66+
Gender: All
MAGIC Ruxolitinib for aGVHD
This clinical trial will study ruxolitinib-based treatment of acute
graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell
transplant. Acute GVHD occurs when donor cells attack the healthy tissue of the body. The
most common symptoms ...
Age: 18 years - 66+
Gender: All
Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
The purpose of this research study is to see if a drug called ritlecitinib is safe and
effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching
lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration
(FDA) to t...
Age: 18 - 65 years
Gender: All
Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
The purpose of this research study is to see if a drug called ritlecitinib is safe and
effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching
lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration
(FDA) to t...
Age: 18 - 65 years
Gender: All
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps
people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to
closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1
ulcer t...
Age: 18 years - 66+
Gender: All
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps
people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to
closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1
ulcer t...
Age: 18 years - 66+
Gender: All
Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)
Recent retrospective studies have demonstrated differences between pulse oximeter values
(SpO2) and measured arterial oxygen saturation (SaO2) in patients identifying as Black or
Hispanic. These retrospective studies have limitations because self-reported race is
lik...
Age: Birth - 18 years
Gender: All
Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)
Recent retrospective studies have demonstrated differences between pulse oximeter values (SpO2) and measured arterial oxygen saturation (SaO2) in patients identifying as Black or Hispanic. These retrospective studies have limitations because self-reported race is likely...
Age: Birth - 18 years
Gender: All
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most frequently affecting the bowels. It can cause
many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
Treatmen...
Age: 18 - 75 years
Gender: All
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most frequently affecting the bowels. It can cause
many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
Treatmen...
Age: 18 - 75 years
Gender: All
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease
which includes the forming of lumps, abscesses and scars in areas of the skin such as
under the breasts, under armpits, inner thighs, groin and buttocks. This study will
compare lu...
Age: 16 years - 66+
Gender: All
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
The purpose of this study is to learn about the safety and effects of 2 study medicines
(PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long-
lasting itchy red rash, caused by a skin reaction.
This study is seeking participants wh...
Age: 18 years - 66+
Gender: All
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
The purpose of this study is to learn about the safety and effects of 2 study medicines
(PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long-
lasting itchy red rash, caused by a skin reaction.
This study is seeking participants wh...
Age: 18 years - 66+
Gender: All
Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections
This protocol describes a randomized, open-label study to evaluate the safety and
tolerability of 2 formulations of single-dose intravenous (IV) oritavancin diphosphate
(Orbactiv and Kimyrsa) for the treatment of pediatric participants with acute bacterial
skin and s...
Age: 3 months - 11 years
Gender: All
Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections
This protocol describes a randomized, open-label study to evaluate the safety and
tolerability of 2 formulations of single-dose intravenous (IV) oritavancin diphosphate
(Orbactiv and Kimyrsa) for the treatment of pediatric participants with acute bacterial
skin and s...
Age: 3 months - 11 years
Gender: All
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene
expression changes of various immune cell and tumor markers in cutaneous metastases
treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1
immune ch...
Age: 18 years - 66+
Gender: All
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two
dosing schedules of cemiplimab given in combination with cisplatin and docetaxel
induction chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of
the head a...
Age: 18 years - 66+
Gender: All
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin
Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the
usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with
HER2 p...
Age: 18 years - 66+
Gender: Female